Inovio Pharmaceuticals, Inc.

Thank you. Thank you. Thank you. Thank you.

Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2026 Financial Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 13, 2026. I would now like to turn the conference over to Jenny Wilson. Please go ahead.

Good afternoon, and thank you for joining the Inovio First Quarter 2026 Financial Results Conference Call. Joining me today on today's call are Dr. Jackie Shea, President and Chief Executive Officer, Dr. Mike Sumner, Chief Medical Officer, Steve Egge, Chief Commercial Officer, and Peter Keys, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended March 31, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question and answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These statements relate to our business plans to develop Inovio's DNA medicines platform, including the FDA's ongoing review of our BLA for INO3107, including the October 30, 2026, PDUFA target date, and our yet to be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program. Our belief that INO3107 fulfills the criteria for accelerated approval, The potential benefits of INO3107, including our belief that it has a positively differentiated product profile, and the potential to become the preferred product by patients and their physicians if approved. The anticipated commercial launch of INO3107 if approved, and our engagement of commercial partners in preparation for a potential launch. Our collaboration with Akizo Inc. to evaluate INO5412 in combination with a novel dual checkpoint inhibitor for the potential treatment of GBM. the advancement of our D-Prot technology platform, capital resources, including our estimated operational net cash burn of approximately $18 million for the second quarter of 2026, and the expected sufficiency of our cash resources into first quarter of 2027, and our expectations regarding competition, market size, and acceptance of INO 3107 if approved. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally, as well as statements made within this afternoon's press release. This call is being webcast live, and a link can be found on our website, ir.inovio.com, and a replay will be made available shortly after this call is concluded. I will now turn the call over to Inovio's President and CEO, Dr. Jackie Shea.